These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
621 related articles for article (PubMed ID: 31732098)
1. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098 [TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM; Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204 [TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185 [TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932 [TBL] [Abstract][Full Text] [Related]
5. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118 [TBL] [Abstract][Full Text] [Related]